Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneFerm Biotechnology CoROCO:1796 -0.64%65 PS Ratio is 1.92 as of Jul. 27, 2026, which is 46% below its 10-year median of 3.55. GuruFocus rates ROCO:1796 with a GF Score™ of 65/100 and a GF Value™ of NT$59.07 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 954 Drug Manufacturers companies, GeneFerm Biotechnology Co ranks better than 55.03% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, GeneFerm Biotechnology Co's share price is NT$31.00.
GeneFerm Biotechnology Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$16.12. Hence, GeneFerm Biotechnology Co's PS Ratio for today is 1.92.
Good Sign:
GeneFerm Biotechnology Co Ltd stock PS Ratio (=1.9) is close to 5-year low of 1.9.
The historical rank and industry rank for GeneFerm Biotechnology Co's PS Ratio or its related term are showing as below:
ROCO:1796'
s PS Ratio Range Over the Past 10 Years
Min: 1.55 Med: 3.55 Max: 9.12
Current: 1.92
During the past 13 years, GeneFerm Biotechnology Co's highest PS Ratio was 9.12. The lowest was 1.55. And the median was 3.55.
ROCO:1796's PS Ratio is ranked better than 55.03% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.255
vs ROCO:1796: 1.92
During the past 12 months, the average Revenue per Share Growth Rate of GeneFerm Biotechnology Co was 29.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 0.10% per year.
During the past 13 years, GeneFerm Biotechnology Co's highest 3-Year average Revenue per Share Growth Rate was 13.50% per year. The lowest was -12.90% per year. And the median was 3.10% per year.
Back to Basics: PS Ratio
GeneFerm Biotechnology Co (ROCO:1796) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
GeneFerm Biotechnology Co PS Ratio Related Terms
GeneFerm Biotechnology Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, GeneFerm Biotechnology Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneFerm Biotechnology Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GeneFerm Biotechnology Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where GeneFerm Biotechnology Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
GeneFerm Biotechnology Co's Share Price of today is NT$31.00. GeneFerm Biotechnology Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$16.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
GeneFerm Biotechnology Co (ROCO:1796) has a PS Ratio of 1.92 as of Jul. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on GeneFerm Biotechnology Co and its competitors. This is 46% below median its historical median of 3.55. Over the past decade, GeneFerm Biotechnology Co's PS Ratio has ranged from 1.55 to 9.12. According to the industry distribution chart, GeneFerm Biotechnology Co ranks #429 out of 954 companies in the Drug Manufacturers industry, placing it in the top 45%.
Is GeneFerm Biotechnology Co's PS Ratio too high?
GeneFerm Biotechnology Co's current PS Ratio of 1.92 is 46% below median its 10-year median of 3.55. Over the past 10 years, this metric has ranged from a low of 1.55 to a high of 9.12. The Drug Manufacturers industry median PS Ratio is 2.26. GeneFerm Biotechnology Co's value of 1.92 is 14.9% below this industry median. Based on the distribution chart, GeneFerm Biotechnology Co ranks #429 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GeneFerm Biotechnology Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GeneFerm Biotechnology Co's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, GeneFerm Biotechnology Co ranks #429 out of 954 companies for PS Ratio. This puts GeneFerm Biotechnology Co in the upper half of its industry. The industry median PS Ratio is 2.26. GeneFerm Biotechnology Co's value of 1.92 is 14.9% below this benchmark. Historically, GeneFerm Biotechnology Co's own PS Ratio has ranged from 1.55 to 9.12 over the past decade. While the company's 10-year median is 3.55 vs. the industry median of 2.26, GeneFerm Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.26, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneFerm Biotechnology Co's current PS Ratio of 1.92 is 14.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on GeneFerm Biotechnology Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneFerm Biotechnology Co's current PS Ratio is 1.92, which is 46% below median its own 10-year median of 3.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneFerm Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co (ROCO:1796) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.07, compared to a current price of NT$31.00 — trading 47.5% below its estimated fair value. The current PS Ratio is 1.92, which is 46% below median its 10-year median of 3.55 and 14.9% below the Drug Manufacturers industry median of 2.26. GeneFerm Biotechnology Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For GeneFerm Biotechnology Co (ROCO:1796), the current PS Ratio is 1.92 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneFerm Biotechnology Co (ROCO:1796) Overvalued in 2026?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co stock appears to be undervalued.
The current stock price of NT$31.00 is trading 47.5% below its estimated GF Value™ of NT$59.07.
GuruFocus considers GeneFerm Biotechnology Co to be Significantly Undervalued.
Key valuation signals for ROCO:1796:
PS Ratio: 1.92 (46% below median its 10-year median of 3.55)
GF Value™: NT$59.07 vs. price of NT$31.00 (47.5% below fair value)
Industry Position: 14.9% below the Drug Manufacturers median (#429 of 954)
No single metric tells the full story. See the ROCO:1796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneFerm Biotechnology Co Ltd is a fermentation company based in Taiwan. It is engaged in manufacturing health food and supplements which include Fermented Microbial products, Fermented Fungi products, Probiotics and Extraction, and Concentration products among others.
65GF Score
Get the complete analysis for ROCO:1796
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1796 has been successfully added to your 
